Shares hit by MS drug suspension

Shares in Elan and Biogen Idec plunged on Monday as the firms suspended sales of new multiple sclerosis drug Tysabri after a patient's death in the US. The companies said they have no reports of the rare condition - progressive multifocal leukoencephalopathy (PML) - in patients taking either Tysabri or Avonex alone. Most of the value in the company was in Tysabri," said Ian Hunter at Goodbody Stockbrokers in Dublin. "